Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer

Paolo Bossi, Gabriela Kornek, Gaetano Lanzetta, Antonio Rozzi, Thorsten Füreder, Laura Locati, Lisa Licitra

Research output: Contribution to journalArticle

Abstract

Background: In patients with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC), there are no data about an every-other-week cetuximab maintenance schedule after chemotherapy plus cetuximab as first-line treatment. Methods: We reviewed the safety and feasibility of every-other-week maintenance cetuximab administered at 3 different European centers. Results: Thirty-one patients with recurrent or metastatic HNSCC were treated from 2006 to 2010. Mean cetuximab dose intensity in the maintenance phase was 93%. The major toxicities reported during every-other-week maintenance cetuximab were skin rash (grade 3, 16%; grade 2, 23%), fatigue (grade 3, 3%; grade 2, 16%), diarrhea (grade 3, 7%; grade 2, 13%), hypomagnesemia (grade 4, 3%; grade 3, 3%; grade 2, 19%), and mucositis (grade 3, 3%; grade 2, 23%). Conclusions: Every-other-week maintenance cetuximab schedule was well tolerated and did not worsen toxicity that occurred during chemotherapy. In daily practice, this simplified schedule could improve compliance and possibly improve quality of life in patients with recurrent or metastatic HNSCC that showed no progression during first-line chemotherapy.

Original languageEnglish
Pages (from-to)1471-1474
Number of pages4
JournalHead and Neck
Volume35
Issue number10
DOIs
Publication statusPublished - Oct 2013

    Fingerprint

Keywords

  • every-other-week cetuximab
  • maintenance therapy
  • quality of life
  • recurrent and/or metastatic head and neck cancer

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this